Clinical trials: Apatinib
Neoplasms
Effect of Rifampicin on the Pharmacokinetics of Apatinib
The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin.
- Trial name
- NCT02836821
- Testing
- Apatinib Mesylate Tablets, Rifampicin Capsules
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HCC
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage.
- Trial name
- NCT07589244
- Testing
- VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Relapsed Ovarian Cancer
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in…
- Trial name
- NCT05479487
- Testing
- Fluzoparib+Apatinib, Fluzoparib Monotherapy
- Volunteers
- 132 people
- Sponsor
- Xiaohua Wu MD
Gastric Cancer
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.
- Trial name
- NCT04258644
- Testing
- Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Extensive-stage Small Cell Lung Cancer, Lung Cancer
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE) has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and the 2-year survival is extremely low.
- Trial name
- NCT03135977
- Testing
- Apatinib, Etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
NSCLC
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
- Trial name
- NCT03634059
- Testing
- Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hebei Medical University Fourth Hospital
Colorectal Cancer
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.
- Trial name
- NCT03397199
- Testing
- Apatinib + S-1
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
Nasopharyngeal Carcinoma
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04073784
- Testing
- Gemcitabine combined with Aptinib and Toripalimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Chemotherapy Combined With Apatinib and PD-1 Antibody
The effective rate of second-line and later-line single-agent therapy for advanced gastric cancer is limited. This research plan aims to explore whether the combination of drugs can further improve the benefits of second-line and…
- Trial name
- NCT05025033
- Testing
- PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extensive-Stage Small Cell Lung Cancer
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT06614621
- Testing
- Adebrelimab +Etoposide+Platinum-based drugs, Maintenance treatment period:
- Volunteers
- 43 people
- Sponsor
- Fujian Cancer Hospital